Open Access
23 December 2013 Contrast enhanced-magnetic resonance imaging as a surrogate to map verteporfin delivery in photodynamic therapy
Author Affiliations +
Abstract
The use of in vivo contrast-enhanced magnetic resonance (MR) imaging as a surrogate for photosensitizer (verteporfin) dosimetry in photodynamic therapy of pancreas cancer is demonstrated by correlating MR contrast uptake to ex vivo fluorescence images on excised tissue. An orthotopic pancreatic xenograft mouse model was used for the study. A strong correlation ([i]r=0.57 ) was found for bulk intensity measurements of T1-weighted gadolinium enhancement and verteporfin fluorescence in the tumor region of interest. The use of contrast-enhanced MR imaging shows promise as a method for treatment planning and photosensitizer dosimetry in human photodynamic therapy (PDT) of pancreas cancer.
CC BY: © The Authors. Published by SPIE under a Creative Commons Attribution 4.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI.
Kimberley S. Samkoe, Amber Bryant, Jason R. Gunn, Stephen P. Pereira, Tayyaba Hasan, and Brian W. Pogue "Contrast enhanced-magnetic resonance imaging as a surrogate to map verteporfin delivery in photodynamic therapy," Journal of Biomedical Optics 18(12), 120504 (23 December 2013). https://doi.org/10.1117/1.JBO.18.12.120504
Published: 23 December 2013
Lens.org Logo
CITATIONS
Cited by 5 scholarly publications.
Advertisement
Advertisement
KEYWORDS
Tumors

Magnetic resonance imaging

Photodynamic therapy

Tissues

Luminescence

Resonance enhancement

Gadolinium

Back to Top